Eli Lilly tasks Nimbus with hitting a 'high-value' target for diabetes, obesity

The computational chemistry experts at Nimbus have always taken pride in selecting compelling targets and deploying a structure-based approach to drug them. Eli Lilly is now swooping in to partner on one such target.